Baseline demographics and clinical characteristics for the short-term and cumulative populations.
| Short-term Period | Cumulative Period, n = 4149 | ||
|---|---|---|---|
| Characteristic | Placebo + Background Therapy, n = 1099 | IV Abatacept + Background Therapy, n = 3173 | |
| Mean age, yrs (SD) | 51.9 (12.0) | 53.0 (12.3) | 52.6 (12.2) |
| Sex (female), n (%) | 884 (80.4) | 2536 (79.9) | 3335 (80.4) |
| Race (white), n (%) | 948 (86.3) | 2824 (89.0) | 3651 (88.0) |
| Mean disease duration, yrs (SD) | 9.7 (8.6) | 10.4 (8.9) | 10.1 (8.8)* |
| Mean physical function, HAQ-DI score (SD) | 1.5 (0.7) | 1.6 (0.6) | 1.6 (0.7) |
| Mean CRP, mg/dl (SD) | 2.6 (2.9) | 2.5 (3.0) | 2.5 (2.9)† |
| Patients receiving MTX, n (%) | 919 (83.6) | 2491 (78.5) | 3332 (80.3) |
| Patients receiving other DMARD, n (%) | 259 (23.6) | 861 (27.1) | 1076 (25.9) |
| Patients receiving biologic RA therapy, n (%) | 84 (7.6) | 239 (7.5) | 296 (7.1) |
| Anti-TNF therapy, n (%) | 74 (6.7) | 217 (6.8) | 265 (6.4) |
| Anakinra, n (%) | 10 (0.9) | 26 (0.8) | 35 (0.8) |
| Rituximab, n (%) | 0 | 1 (< 0.1) | 1 (< 0.1) |